|
1
|
Sharpe M and Mount N: Genetically modified
T cells in cancer therapy: Opportunities and challenges. Dis Model
Mech. 8:337–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Casucci M, Hawkins RE, Dotti G and
Bondanza A: Overcoming the toxicity hurdles of genetically targeted
T cells. Cancer Immunol Immunother. 64:123–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cameron BJ, Gerry AB, Dukes J, Harper JV,
Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, et al:
Identification of a Titin-derived HLA-A1-presented peptide as a
cross-reactive target for engineered MAGE A3-directed T cells. Sci
Transl Med. 5:197ra1032013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johnson LA, Morgan RA, Dudley ME, Cassard
L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich
JR, et al: Gene therapy with human and mouse T-cell receptors
mediates cancer regression and targets normal tissues expressing
cognate antigen. Blood. 114:535–546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkhurst MR, Yang JC, Langan RC, Dudley
ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry
RM, et al: T cells targeting carcinoembryonic antigen can mediate
regression of metastatic colorectal cancer but induce severe
transient colitis. Mol Ther. 19:620–626. 2011. View Article : Google Scholar
|
|
6
|
Morgan RA, Chinnasamy N, Abate-Daga D,
Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry
RM, et al: Cancer regression and neurological toxicity following
anti-MAGE-A3 TCR gene therapy. J Immunother. 36:133–151. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Linette GP, Stadtmauer EA, Maus MV,
Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM,
Cimino PJ, et al: Cardiovascular toxicity and titin
cross-reactivity of affinity-enhanced T cells in myeloma and
melanoma. Blood. 122:863–871. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Loenen MM, De Boer R, Amir AL,
Hagedoorn RS, Volbeda GL, Willemze R, van Rood JJ, Falkenburg JH
and Heemskerk MH: Mixed T cell receptor dimers harbor potentially
harmful neoreactivity. Proc Natl Acad Sci USA. 107:10972–10977.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bendle GM, Linnemann C, Hooijkaas AI, Bies
L, De Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback
E, et al: Lethal graft-versus-host disease in mouse models of T
cell receptor gene therapy. Nat Med. 16:565–570. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA
and Morgan RA: Enhanced antitumor activity of murine-human hybrid
T-cell receptor (TCR) in human lymphocytes is associated with
improved pairing and TCR/CD3 stability. Cancer Res. 66:8878–8886.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen CJ, Li YF, El-Gamil M, Robbins PF,
Rosenberg SA and Morgan RA: Enhanced antitumor activity of T cells
engineered to express T-cell receptors with a second disulfide
bond. Cancer Res. 67:3898–3903. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Voss RH, Willemsen RA, Kuball J, Grabowski
M, Engel R, Intan RS, Guillaume P, Romero P, Huber C and Theobald
M: Molecular design of the Calphabeta interface favors specific
pairing of introduced TCRalphabeta in human T cells. J Immunol.
180:391–401. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aggen DH, Chervin AS, Schmitt TM, Engels
B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD,
Schreiber H and Kranz DM: Single-chain VαVβ T-cell receptors
function without mispairing with endogenous TCR chains. Gene Ther.
19:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ochi T, Fujiwara H, Okamoto S, An J, Nagai
K, Shirakata T, Mineno J, Kuzushima K, Shiku H and Yasukawa M:
Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector
encoding silencers for endogenous TCRs shows marked antileukemia
reactivity and safety. Blood. 118:1495–1503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Provasi E, Genovese P, Lombardo A, Magnani
Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, et al:
Editing T cell specificity towards leukemia by zinc finger
nucleases and lentiviral gene transfer. Nat Med. 18:807–815. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van der Veken LT, Coccoris M, Swart E,
Falkenburg JH, Schumacher TN and Heemskerk MH: Alpha beta T cell
receptor transfer to gamma delta T cells generates functional
effector cells without mixed TCR dimers in vivo. J Immunol.
182:164–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marcu-Malina V, Heijhuurs S, van Buuren M,
Hartkamp L, Strand S, Sebestyen Z, Scholten K, Martens A and Kuball
J: Redirecting αβ T cells against cancer cells by transfer of a
broadly tumor-reactive γδT-cell receptor. Blood. 118:50–59. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tao C, Shao H, Yuan Y, Wang H, Zhang W,
Zheng W, Ma W and Huang S: Imaging of T-cell receptor fused to CD3ζ
reveals enhanced expression and improved pairing in living cells.
Int J Mol Med. 34:849–855. 2014.PubMed/NCBI
|
|
19
|
Jang YY, Cho D, Kim SK, Shin DJ, Park MH,
Lee JJ, Shin MG, Shin JH, Suh SP and Ryang DW: An improved flow
cytometry-based natural killer cytotoxicity assay involving calcein
AM staining of effector cells. Ann Clin Lab Sci. 42:42–49.
2012.PubMed/NCBI
|
|
20
|
De Libero G, Lau SY and Mori L:
Phosphoantigen presentation to TCR γδ Cells, a conundrum getting
less gray zones. Front immunol. 5:6792014.PubMed/NCBI
|
|
21
|
Scheper W, Sebestyen Z and Kuball J:
Cancer Immunotherapy using γδT cells: Dealing with diversity. Front
Immunol. 5:6012014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuhns MS, Davis MM and Garcia KC:
Deconstructing the form and function of the TCR/CD3 complex.
Immunity. 24:133–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heemskerk MH, Hagedoorn RS, van der Hoorn
MA, van der Veken LT, Hoogeboom M, Kester MG, Willemze R and
Falkenburg JH: Efficiency of T-cell receptor expression in
dual-specific T cells is controlled by the intrinsic qualities of
the TCR chains within the TCR-CD3 complex. Blood. 109:235–243.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Teixeiro E, Daniels MA, Hausmann B, Schrum
AG, Naeher D, Luescher I, Thome M, Bragado R and Palmer E: T cell
division and death are segregated by mutation of TCRbeta chain
constant domains. Immunity. 21:515–526. 2004. View Article : Google Scholar : PubMed/NCBI
|
